What's in Universitaire Ziekenhuizen KU Leuven's pipeline?

Universitaire Ziekenhuizen KU Leuven has 41 drugs in our index: 30 marketed, 0 filed, 5 in Phase 3, 4 in Phase 2, 2 in Phase 1.

Which companies overlap with Universitaire Ziekenhuizen KU Leuven's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Chang Gung Memorial Hospital, Daiichi Sankyo Co., Ltd., Kasr El Aini Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universitaire-ziekenhuizen-ku-leuven.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Universitaire Ziekenhuizen KU Leuven — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Universitaire Ziekenhuizen KU Leuven pipeline: 30 marketed, 0 filed, 5 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

30 marketed 0 filed 5 Phase 3 4 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Area
Preserved drop treatment	Preserved drop treatment	marketed
Pantoprazole 40mg	Pantoprazole 40mg	marketed
Ora-Plus	Ora-Plus	marketed
Corticotropin-release hormone	Corticotropin-release hormone	marketed
Nalcrom	Nalcrom	marketed	Other
Siripus simplex	Siripus simplex	marketed	Psychiatry
Ursochol oral tablet	Ursochol oral tablet	marketed
Natural cycle	Natural cycle	marketed
Apixaban steady-state	Apixaban steady-state	marketed
Rikkunshito	Rikkunshito	marketed	Other
Buspirone Hydrochloride 10 MG	Buspirone Hydrochloride 10 MG	marketed
Timolol & Dorzolamide	Timolol & Dorzolamide	marketed

Therapeutic area mix

Other · 7
Ophthalmology · 3
Gastroenterology · 3
Oncology · 2
Psychiatry/Neurology · 2
Cardiovascular · 2
Neurology / Musculoskeletal · 1
Psychiatry · 1
Psychiatry / Mental Health · 1
Regenerative Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 2 shared drug classes
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 2 shared drug classes
Chang Gung Memorial Hospital · 2 shared drug classes
Daiichi Sankyo Co., Ltd. · 2 shared drug classes
Kasr El Aini Hospital · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Bayer · 2 shared drug classes
UCB Pharma · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Universitaire Ziekenhuizen KU Leuven:

Cite this brief

Drug Landscape (2026). Universitaire Ziekenhuizen KU Leuven — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universitaire-ziekenhuizen-ku-leuven. Accessed 2026-05-17.